To assess the absorption, distribution, metabolism and excretion of a single dose of 14C labelled AZD1722 in order to define the rates and routes of elimination of AZD1722 and if formed, metabolites.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
26
Single oral dose 15 mg of \[14C\]AZD1722
Research Site
London, United Kingdom
Percentage of radioactive dose recovered in urine and feces
Time frame: Day 1: Pre-dose and up to 168 hours post-dose
Total percentage of radioactive dose recovered from both urine and feces
Time frame: Day 1: Pre-dose and up to 168 hours post-dose
Concentration of total radioactivity in blood and plasma samples
Time frame: Timeframe: Day 1: Predose and up to 120 hours
Concentration of AZD1722 in plasma samples
Time frame: Timeframe: Day 1: Predose and up to 120 hours
Safety variables (adverse events, vital signs, ECGs, clinical laboratory tests)
Time frame: up to 50 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.